Century Therapeutics grants 74,000 stock options

Century Therapeutics, Inc. reported that director Lee Han Myung received a grant of stock options covering 74,000 shares of common stock.

Rhea-AI Filing Summary

Century Therapeutics, Inc. reported that director Lee Han Myung received a grant of stock options covering 74,000 shares of common stock. The options have an exercise price of $2.24 per share and expire on June 11, 2036.

The option award vests on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, in each case only if Lee Han Myung continues to serve through the vesting date. Following this grant, the filing shows holdings of 74,000 stock options directly.

Insider Trade Summary

Grant/Award: 74,000 shares

Grant/Award 1 txn

Insider Lee Han Myung

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	74,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 74,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Option grant size: 74,000 options Exercise price: $2.24 per share Underlying shares: 74,000 shares +3 more

6 metrics

Option grant size 74,000 options Stock Option (right to buy) awarded to director

Exercise price $2.24 per share Conversion or exercise price for the stock options

Underlying shares 74,000 shares Underlying Century Therapeutics common stock

Total options after grant 74,000 options Total derivative holdings following the transaction

Vesting date June 11, 2027 (or earlier meeting) Earlier of June 11, 2027 or next annual meeting, with continued service

Expiration date June 11, 2036 Option expiration for the granted stock options

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, underlying security, vesting date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

underlying security financial

"underlying_security_title: Common Stock"

vesting date financial

"subject to the Reporting Person's continued service through the applicable vesting date"

annual meeting of stockholders financial

"the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Century Therapeutics (IPSC) director Lee Han Myung receive in this Form 4?

Lee Han Myung received a stock option grant for 74,000 shares of Century Therapeutics common stock. This is a compensation-related award, not an open-market trade, and gives the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the new Century Therapeutics (IPSC) stock options?

The new stock options have an exercise price of $2.24 per share. This means Lee Han Myung can purchase Century Therapeutics common shares at $2.24 once the options vest and before they expire, regardless of the market price at that time.

When do Lee Han Myung’s Century Therapeutics (IPSC) options vest?

The options vest on the earlier of June 11, 2027 or the next annual meeting of stockholders. Vesting in both cases depends on Lee Han Myung continuing to serve the company through the applicable vesting date, as noted in the filing footnote.

When do the Century Therapeutics (IPSC) options granted to Lee Han Myung expire?

The granted stock options expire on June 11, 2036. After that date, any unexercised options lapse and can no longer be used to buy Century Therapeutics common shares, so the effective exercise window runs between vesting and this expiration date.

How many Century Therapeutics (IPSC) options does Lee Han Myung hold after this grant?

After this award, the Form 4 reports that Lee Han Myung holds 74,000 stock options. These options are reported as a direct holding and correspond to an equal number of underlying Century Therapeutics common shares, subject to vesting and the stated exercise terms.

Is this Century Therapeutics (IPSC) Form 4 a buy or sell transaction?

This Form 4 reflects an option grant, categorized as an acquisition rather than a market buy or sell. The transaction code is “A,” meaning a grant or award, and no open-market purchases or sales of Century Therapeutics common stock are reported here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Han Myung

(Last) (First) (Middle)

25 N 38TH ST.

11TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.24	06/11/2026		A		74,000		(1)	06/11/2036	Common Stock	74,000	$0	74,000	D

Explanation of Responses:

1. The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Douglas Carr, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)